2 days Ago
Texas-based biotechnology firm Gameto developed a more accessible alternative to in vitro fertilization called Fertilo. Instead of relying on hormone injections to mature eggs, it uses ovarian support cells (OSC) to promote egg maturation in a laboratory. On December 16, 2024, the biotech company announced the birth of the first Fertilo baby.
Dr. Luis Guzmán, Lead at Pranor Labs & Science in Peru, oversaw the procedure. (2/) Fertilo is an iPSC-derived solution aimed at improving IVF/egg freezing by recreating the natural egg maturation process outside the body, decreasing the traditional 10-14 days of hormone injections to 3 days or less, reducing the cycle duration and associated side effects.
The official Gameto website says Fertilo moves the egg maturation process outside the body. As a result, it provides a shorter, easier, and more accessible in vitro fertilization (IVF). Here’s how it works: Dr.
Luis Guzmán explained the advantages of Fertilo over conventional IVF: “The ability to mature eggs outside the body with minimal hormonal intervention significantly reduces risks such as ovarian hyperstimulation syndrome and alleviates the side effects caused by high hormone doses.” He oversaw the first live human birth using the Fertilo method at the Santa Isabel Clinic in Lima, Peru. The child’s mother shared her gratitude for the novel approach.
“With fewer injections and a gentler, less invasive egg retrieval process, it gave me hope and reassurance during a deeply personal journey,” she said. Gameto says the US hasn’t approved Fertilo yet, but the FDA has provided tentative approval for a Phase 3 trial. Subscribe to our daily newsletter By providing an email address.
I agree to the Terms of Use and acknowledge that I have read the Privacy Policy ..
